TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23732265

Group type: EXPERIMENTAL
Intervention: Outpatient management (group 2)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Hospitalization management (group 1)
Number of subjects: 132
Study: 23788832

Group type: EXPERIMENTAL
Intervention: Preventive home visits (up to three visits including risk assessment, home counseling intervention, and a booster session)
Number of subjects: 230

Group type: COMPARATOR
Intervention: No preventive home visits (Control group)
Number of subjects: 230
Study: 20839435

Group type: EXPERIMENTAL
Intervention: Trial group (remnant ACL)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no remnant ACL)
Number of subjects: 97
Study: 17825472

Group type: EXPERIMENTAL
Intervention: Skin closure by staples with closure of subcutaneous space
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Skin closure by staples with non-closure of subcutaneous space
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intracutaneous suture with closure of subcutaneous space
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Intracutaneous suture with non-closure of subcutaneous space
Number of subjects: 153
Study: 16389216

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (18, 36, 54, or 72 mg once daily)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: COMPARATOR
Intervention: OROS methylphenidate and Placebo
Number of subjects: 220
Study: 12930332

Group type: EXPERIMENTAL
Intervention: High-power 50-ms 1064 Nd:YAG laser treatment
Number of subjects: 10
Study: 11293738

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mcg/kg) administered intravenously within 1 hour of surgery and every 12 hours thereafter, switched to enteral captopril (3 mg/kg/day) every 8 hours when tolerating feeds.
Number of subjects: 36

Group type: COMPARATOR
Intervention: No angiotensin converting enzyme inhibitors administered (Control group).
Number of subjects: 36
Study: 9226707

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 60
Study: 8433561

Group type: EXPERIMENTAL
Intervention: Insulin with dextrose infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epinephrine infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion with insulin and glucose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting without intervention
Number of subjects: 10
Study: 3303247

Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-administered group
Number of subjects: 0
Study: 31690117

Group type: EXPERIMENTAL
Intervention: ShotBlocker™ device
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (device with projections removed)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 30479287

Group type: EXPERIMENTAL
Intervention: Anesthetic cream (2.5% lidocaine/2.5% prilocaine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 27683967

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy for complicated grief (CG) treatment
Number of subjects: 151
Study: 26577943

Group type: EXPERIMENTAL
Intervention: Home group (oral amoxicillin treatment at home)
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Hospital group (oral amoxicillin treatment in hospital for first 48 hours)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Home group
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Hospital group
Number of subjects: 1118
Study: 24244656

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (3 times a week for 12 weeks, aerobic exercise at 55‐75% maximum heart rate for 60 min, resistance exercise with barbells 1‐3 kg and resistance bands)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual physical activity (Control group)
Number of subjects: 20
Study: 21124314

Group type: EXPERIMENTAL
Intervention: DX-619
Number of subjects: 0
Study: 19034749

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 to 120 mg QD, titrated based on response, with 90 mg QD as an intermediate dose)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 249
Study: 17162316

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine/zidovudine qd plus efavirenz qd (QD arm)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abacavir/lamivudine/zidovudine bid plus efavirenz qd (BID arm)
Number of subjects: 36
Study: 12667566

Group type: EXPERIMENTAL
Intervention: ICD therapy after VT
Number of subjects: 449

Group type: COMPARATOR
Intervention: ICD therapy after VF
Number of subjects: 449
Study: 11108507

Group type: EXPERIMENTAL
Intervention: Phenytoin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticonvulsant levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subtherapeutic levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacodynamic factors
Number of subjects: 0
Study: 9183334

Group type: EXPERIMENTAL
Intervention: rt-PA and heparin therapy
Number of subjects: 3924
Study: 30635271

Group type: EXPERIMENTAL
Intervention: Nivolumab followed by ipilimumab (nivo/ipi)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Ipilimumab followed by nivolumab (ipi/nivo)
Number of subjects: 113
Study: 30007160

Group type: EXPERIMENTAL
Intervention: Guanfacine 0.1 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Guanfacine (both doses)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 123
Study: 27543458

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (ECs) containing 2.4%, 1.8% or 0% nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (ECs)
Number of subjects: 0
Study: 24299276

Group type: EXPERIMENTAL
Intervention: Poison prevention video module
Number of subjects: 297

Group type: COMPARATOR
Intervention: Usual class curriculum (control)
Number of subjects: 297
Study: 22573644

Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin (10-20 mg/d)
Number of subjects: 2636
Study: 18302459

Group type: EXPERIMENTAL
Intervention: Hyrax appliance and reverse headgear (UCLP group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hyrax appliance and reverse headgear (noncleft group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: UCLP group
Number of subjects: 36
Study: 16442264

Group type: EXPERIMENTAL
Intervention: Combined technique using nitrous oxide/oxygen and intravenous Midazolam
Number of subjects: 0
Study: 12897376

Group type: EXPERIMENTAL
Intervention: Fasting insulin measurement
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: QUICKI
Number of subjects: 321
Study: 10907363

Group type: EXPERIMENTAL
Intervention: ACEI (enarenal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9431825

Group type: EXPERIMENTAL
Intervention: Fat-rich meal (ethanol consumed after meal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CHO-rich meal (ethanol consumed after meal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Protein-rich meal (ethanol consumed after meal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasting (ethanol consumed on an empty stomach)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous infusion (ethanol administered by i.v. infusion)
Number of subjects: 9
Study: 8277056

Group type: EXPERIMENTAL
Intervention: Dental digital radiology
Number of subjects: 0
Study: 3029792

Group type: EXPERIMENTAL
Intervention: Marijuana (1.2% THC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cannabinoid-exhausted marijuana (placebo)
Number of subjects: 12
Study: 29729702

Group type: EXPERIMENTAL
Intervention: Kidney Flaccidity Compound (KFC) for 1.5 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kidney Flaccidity Compound (KFC) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kidney Flaccidity Compound (KFC)
Number of subjects: 0
Study: 27780109

Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training (n=43)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Home-based exercise (n=42)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 85
Study: 25710119

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 168
Study: 23885616

Group type: EXPERIMENTAL
Intervention: Round-sharp needle of new nine-needle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Elongated needle treatment
Number of subjects: 80
Study: 20629511

Group type: EXPERIMENTAL
Intervention: Genomic approaches to treatment response including detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes, and differential gene-expression patterns.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic approaches to treatment response
Number of subjects: 0
Study: 19056701

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Aclasta ‐ Novartis)
Number of subjects: 0
Study: 17062711

Group type: EXPERIMENTAL
Intervention: Multistate model for evaluating skeletal events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple methods of analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multistate approach
Number of subjects: 0
Study: 12612867

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study: 10801170

Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade (MAB)
Number of subjects: 8275

Group type: COMPARATOR
Intervention: Androgen suppression (AS) alone
Number of subjects: 8275

Group type: COMPARATOR
Intervention: Cyproterone acetate (part of MAB)
Number of subjects: 8275

Group type: EXPERIMENTAL
Intervention: Nilutamide and flutamide (part of MAB)
Number of subjects: 8275
Study: 9200137

Group type: EXPERIMENTAL
Intervention: Prenatal cigarette exposure
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Postnatal secondhand smoke exposure
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Prenatal marijuana exposure
Number of subjects: 131

Group type: COMPARATOR
Intervention: Maternal prenatal passive smoke exposure
Number of subjects: 131
Study: 1376839

Group type: EXPERIMENTAL
Intervention: Modified-release formulation of isradipine (Im) at 5 mg once daily
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard formulation of isradipine (Is) at 2.5 mg twice daily
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Modified-release formulation of isradipine (Im)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard formulation of isradipine (Is)
Number of subjects: 380
Study: 2864027

Group type: EXPERIMENTAL
Intervention: Cognitive training (16-week program emphasizing reflective problem-solving strategies and social problem-solving skills)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training
Number of subjects: 0
Study: 31726876

Group type: EXPERIMENTAL
Intervention: G-estimation method for treatment on the outcome (physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G-estimation method
Number of subjects: 0
Study: 29946655

Group type: EXPERIMENTAL
Intervention: Modified scene simulation teaching method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 40
Study: 28793896

Group type: EXPERIMENTAL
Intervention: MEDI8968 300 mg subcutaneously every 4 weeks (600 mg intravenous loading dose) for 52 weeks
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: MEDI8968 300 mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: MEDI8968 and Placebo
Number of subjects: 324
Study: 26589192

Group type: EXPERIMENTAL
Intervention: Kinesio-Taping (K-Tape)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24294677

Group type: EXPERIMENTAL
Intervention: SBAR forms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cases (no SBAR forms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SBAR cases
Number of subjects: 20
Study: 21426232

Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg every 12 hours for 6 months (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo every 12 hours for 6 months (n=50)
Number of subjects: 100
Study: 18279183

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP plus azithromycin
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP plus metronidazole
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SRP plus sub-antimicrobial dose of doxycycline
Number of subjects: 92
Study: 17262127

Group type: EXPERIMENTAL
Intervention: Carisolv gel + SRP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo gel + SRP
Number of subjects: 45

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 45
Study: 12527536

Group type: EXPERIMENTAL
Intervention: Functional adaptation skills training (FAST) group therapy program (24 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 40
Study: 10770538

Group type: COMPARATOR
Intervention: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV; 200 mg three times per day) plus lamivudine (3TC; 150 mg twice per day) plus indinavir (IND; 800 mg q8h)
Number of subjects: 103
Study: 9581003

Group type: EXPERIMENTAL
Intervention: Physician intervention
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 175

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 175
Study: 8443934

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg twice daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3098131

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30962688

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 0
Study: 28264663

Group type: EXPERIMENTAL
Intervention: Routine counselling plus additional problem-solving for caregivers
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine counselling alone
Number of subjects: 58
Study: 25869157

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid load (BAL)
Number of subjects: 18
Study: 23953322

Group type: EXPERIMENTAL
Intervention: Ketamine (0.227 mg/kg for ED50; 0.283 mg/kg for ED95)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 50
Study: 20560900

Group type: EXPERIMENTAL
Intervention: Sertindole 12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertindole 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertindole 24 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol 16 mg
Number of subjects: 0
Study: 19208045

Group type: EXPERIMENTAL
Intervention: Tactile-only stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multisensory intervention (auditory, tactile, visual, and vestibular)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 40
Study: 17869975

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 mg/d after a 70-mg loading dose)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.6-1.0 mg/kg per day)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 224

Group type: COMPARATOR
Intervention: Caspofungin and Amphotericin B
Number of subjects: 224
Study: 15491237

Group type: EXPERIMENTAL
Intervention: ACASI survey self‐administered through an Internet browser using a touchscreen
Number of subjects: 90

Group type: COMPARATOR
Intervention: In-person interview
Number of subjects: 90
Study: 11505696

Group type: EXPERIMENTAL
Intervention: Soft type margarine (30 g total per day, 15 g twice a day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Butter (30 g total per day, 15 g twice a day)
Number of subjects: 83
Study: 9752402

Group type: EXPERIMENTAL
Intervention: Shouldice repair (S group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Laparoscopic repair (L group)
Number of subjects: 64
Study: 7822582

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Depressed control patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 60
Study: 3397041

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8
Study: 31650328

Group type: EXPERIMENTAL
Intervention: High-fibre intake (39 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre intake (18 g/day)
Number of subjects: 10
Study: 31368270

Group type: EXPERIMENTAL
Intervention: Headache-acupoint group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-acupoint group
Number of subjects: 40
Study: 28905240

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mixed (aerobic and resistance) training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 25037189

Group type: EXPERIMENTAL
Intervention: Increased intake of resistant starch (RS) and wheat bran (WB)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy subjects), n=10
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Increasing RS/WB intake
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Faeces from UC cohort
Number of subjects: 19
Study: 23862170

Group type: EXPERIMENTAL
Intervention: 14-day triple therapy
Number of subjects: 314

Group type: COMPARATOR
Intervention: 7-day triple therapy
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: 14-day triple therapy (subgroup)
Number of subjects: 314

Group type: COMPARATOR
Intervention: 7-day triple therapy (subgroup)
Number of subjects: 314
Study: 21781448

Group type: EXPERIMENTAL
Intervention: Insertion torque of 35N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insertion torque of 50N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insertion torque of 65N
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insertion torque of 85N
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (insertion torque of 35N and 50N)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental group (insertion torque of 65N and 85N)
Number of subjects: 20
Study: 17934721

Group type: EXPERIMENTAL
Intervention: 1.0 mg of nicotine delivered via nasal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative arousal from an unsolvable anagram task
Number of subjects: 0
Study: 17071438

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 2 g/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 10 mg twice-daily
Number of subjects: 100
Study: 12940394

Group type: EXPERIMENTAL
Intervention: High-dose nicotine patch (35 mg)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 158
Study: 10740110

Group type: EXPERIMENTAL
Intervention: Fenspiride (Pneumorel 80mg) plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo plus antibiotic therapy (Amoxicillin 500mg plus clavulanic acid 125, 3 tablets/day)
Number of subjects: 39
Study: 9200635

Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate hydrochloride (LAAM) high-dose condition (100/100/140 mg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate hydrochloride (LAAM) medium-dose condition (50/50/70 mg)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Levomethadyl acetate hydrochloride (LAAM) low-dose condition (25/25/35 mg)
Number of subjects: 180
Study: 8261875

Group type: EXPERIMENTAL
Intervention: 50 mg of methadone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 20 mg of methadone
Number of subjects: 95

Group type: COMPARATOR
Intervention: methadone-free treatment
Number of subjects: 95
Study: 6383114

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 31215440

Group type: EXPERIMENTAL
Intervention: QbTest added to medication management
Number of subjects: 21
Study: 29843676

Group type: EXPERIMENTAL
Intervention: Intake of typical antipsychotics
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Being employed
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Higher level of global functioning
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Having social support
Number of subjects: 127

Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 127
Study: 27084979

Group type: EXPERIMENTAL
Intervention: Group 1 - referred to as 'people/person with epilepsy'
Number of subjects: 234

Group type: COMPARATOR
Intervention: Group 2 - referred to as 'epileptic/s'
Number of subjects: 234